BOSTON and LONDON, Aug. 10, 2016 /PRNewswire/ -- CSA Medical announces its upcoming mini-symposium at the ERS Conference, taking place on Tuesday, September 6, 2016 in London, England. The symposium will highlight early data from its feasibility study utilizing the RejuvenAir® Metered Cryospray™ System, which is under development for the treatment of chronic bronchitis.
The symposium will be chaired by James Donohue, MD (Chapel Hill, USA). Presenters will be Gerard Criner, MD (Philadelphia, USA), Ellen Sheets, MD (Lexington, USA), James Coad, MD (Morgantown, USA), Dirk-Jan Slebos, MD (Groningen, NL), and Pallav Shah, MD (London, UK).
"This symposium marks a milestone in the RejuvenAir program, as the data we will present encompasses the initial treatment of chronic bronchitis patients and their 60 day follow-up. This, combined with our first public disclosure of the science behind the RejuvenAir System, will convey how the rejuvenative properties of liquid nitrogen may be beneficial to chronic bronchitis patients," said Ellen Sheets, MD, CEO CSA Medical.
Chronic bronchitis is a subset of Chronic Obstructive Pulmonary Disease (COPD). A chronic bronchitis diagnosis is defined by cough with productive sputum of three months duration for two consecutive years. In addition to a chronic inflammation, cough and increased production of mucus, chronic bronchitis may or may not present with obstruction/partially blocked airways due to swelling and excess mucus in the bronchi, or shortness of breath (dyspnea).
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze system which uses Liquid Nitrogen spray that has a boiling point of -196oC to ablate unwanted benign and malignant tissue. The RejuvenAir System is currently under clinical investigation and is not commercially available.
To learn more about our technology, please visit www.csamedical.com.
PRLog ID: www.prlog.org/12579068
SOURCE CSA Medical